Related news from
Tue, 16 Apr 2024 12:00:00 +0000	MIMEDX to Host First Quarter 2024 Operating and Financial Results Conference Call on April 30 MARIETTA, Ga., April 16, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the first quarter ended March 31, 2024 after the market close on Tuesday, April 30, 2024. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day. The conference call can be accessed using the following information: Webc
Thu, 11 Apr 2024 11:45:00 +0000	MDXG: Legal Avenues By John Vandermosten, CFA NASDAQ:MDXG READ THE FULL MDXG RESEARCH REPORT Since the report of 2023 full year results on February 28th, MiMedx Group, Inc. (NASDAQ:MDXG) has received an update on its request for designation for Axiofill from the FDA. It has also signed a commercialization agreement with TELA Bio to distribute xenograft products, introduced an e-commerce and account management
Wed, 27 Mar 2024 12:00:00 +0000	MIMEDX Provides Update on AXIOFILL® Request for Designation (“RFD”) from FDA Receives Determination Letter from FDA Stating AXIOFILL Does Not Qualify for Classification as an HCT/P Under Section 361 MIMEDX Continues to Pursue All Available Options to Keep AXIOFILL on the Market Reiterates Expectations for 2024 Net Sales Percentage Growth in the Low Double Digits and 2024 Adjusted EBITDA1 Margin Above 20% MARIETTA, Ga., March 27, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that the U.S. Food and Drug Administratio
Thu, 21 Mar 2024 18:57:40 +0000	Investing in MiMedx Group (NASDAQ:MDXG) a year ago would have delivered you a 138% gain Unless you borrow money to invest, the potential losses are limited. But if you pick the right stock, you can make a...
Wed, 20 Mar 2024 11:00:00 +0000	MIMEDX Expands Portfolio with Fibrillar Collagen Wound Dressing Exclusive agreement provides MIMEDX with rights to commercialize 510(k) cleared, bovine-derived collagen matrix particulate that is indicated for the management of exudating woundsMARIETTA, Ga., March 20, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it has entered into an agreement with TELA Bio, Inc. to obtain exclusive rights to its manufacturing and supply agreement with Regenity Biosciences that will enable the Company to add xen
Wed, 13 Mar 2024 12:00:00 +0000	MIMEDX Introduces E-Commerce and Account Management Platform Designed to Streamline Ordering, Payment Processing, and Reimbursement SubmissionsMARIETTA, Ga., March 13, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the launch of MIMEDX Connect™, an online product ordering and account management portal available to its customers through the Company’s website. “In our ongoing commitment to improve our customers’ experience, we are excited to introduce the MIMEDX Connect platform, which is designed to s
Mon, 04 Mar 2024 13:00:00 +0000	MIMEDX Announces Appointment of Two New Independent Directors MARIETTA, Ga., March 04, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the appointments of Tiffany Olson and Dorothy Puhy to its Board of Directors, effective as of March 1, 2024. Ms. Olson and Ms. Puhy each bring extensive and relevant experience across the healthcare industry, with demonstrated records of executive leadership, strategic counsel and shareholder value creation. In connection with these appointments, the Board of Directors
Fri, 01 Mar 2024 10:11:05 +0000	MiMedx Group, Inc.'s (NASDAQ:MDXG) Stock's On An Uptrend: Are Strong Financials Guiding The Market? MiMedx Group (NASDAQ:MDXG) has had a great run on the share market with its stock up by a significant 5.4% over the...
Fri, 01 Mar 2024 10:10:18 +0000	MiMedx Group Full Year 2023 Earnings: EPS Beats Expectations MiMedx Group ( NASDAQ:MDXG ) Full Year 2023 Results Key Financial Results Revenue: US$321.5m (up 20% from FY 2022). Net...
Thu, 29 Feb 2024 15:49:14 +0000	MiMedx Group, Inc. (NASDAQ:MDXG) Q4 2023 Earnings Call Transcript MiMedx Group, Inc. (NASDAQ:MDXG) Q4 2023 Earnings Call Transcript February 28, 2024 MiMedx Group, Inc. misses on earnings expectations. Reported EPS is $0.04 EPS, expectations were $0.08. MiMedx Group, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings, and […]
Thu, 29 Feb 2024 11:27:00 +0000	MDXG: Another Beat & Raise By John Vandermosten, CFA NASDAQ:MDXG READ THE FULL MDXG RESEARCH REPORT 2023 Financial and Operational Summary MiMedx Group, Inc. (NASDAQ:MDXG) reported full year 2023 revenues of $321.5 million, representing a 20% year over year growth rate, surpassing our $320 million estimate. Pre-tax income was $30.6 million, benefiting from lower expenses on every line. A tax benefit was recognized,
Wed, 28 Feb 2024 21:55:03 +0000	MiMedx Group Inc (MDXG) Reports Strong Year-Over-Year Sales Growth and Net Income Surge in Q4 ... Robust Financial Performance Highlighted by 20% Annual Sales Increase and Significant Net Income Growth
Wed, 28 Feb 2024 21:01:00 +0000	MIMEDX Announces Fourth Quarter and Full Year 2023 Operating and Financial Results Net Sales Grew 17% Year-Over-Year for the Fourth Quarter and 20% for the Full Year Fourth Quarter Net Income was $53 million, Inclusive of a $40 million One-Time Non-Cash Tax Benefit Fourth Quarter Adjusted EBITDA of $21 million, or 24% of Net Sales Management to Host Conference Call Today, February 28, 2024, at 4:30 PM ET MARIETTA, Ga., Feb. 28, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), today announced operating and financial results for the fourth
Thu, 22 Feb 2024 04:51:31 +0000	MiMedx Group Inc Insider Sells Shares Ricci Whitlow, the COO of MiMedx Group Inc (NASDAQ:MDXG), executed a sale of 30,764 shares in the company on February 20, 2024, according to a recent SEC Filing.
Tue, 20 Feb 2024 13:00:00 +0000	MIMEDX to Present at TD Cowen 44th Annual Health Care Conference MARIETTA, Ga., Feb. 20, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that senior management will participate in the TD Cowen 44th Annual Health Care Conference. TD Cowen | Boston, MA | March 4-6, 2024Presentation: Monday, March 4, 2024 at 2:10 PM ETWebcast: Click here to access Institutional investors interested in meeting with senior management may contact their TD Cowen representative. A live webcast of the presentation will be availabl
Tue, 13 Feb 2024 17:58:23 +0000	Get Rich Quick With These 3 Biotech Stocks to Buy Now I have always said it, and I keep my word regarding the biotechnology sector, since it is one of the largest and most important sectors. Not only is it vital for the financial markets, but for the quality of human life. Thanks to companies in this sector, there are innovative and completely effective solutions for very complicated diseases. If you want to participate and contribute to companies in charge of improving human health, here are three biotech stocks to buy. Let’s take a quick look at
Mon, 12 Feb 2024 13:00:00 +0000	MIMEDX to Host Fourth Quarter and Full Year 2023 Operating and Financial Results Conference Call on February 28 MARIETTA, Ga., Feb. 12, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the fourth quarter and full year ended December 31, 2023 after the market close on Wednesday, February 28, 2024. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day. The conference call can be accessed using the follo
Mon, 22 Jan 2024 13:00:00 +0000	MIMEDX Announces Improved Capital Structure with New Senior Secured Credit Facilities and Debt Refinancing New Credit Facilities Provide Substantial Interest Savings and Access to Additional Capital to Support Execution of Strategic PrioritiesMARIETTA, Ga., Jan. 22, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it has enhanced its capital structure by refinancing its existing indebtedness and obtaining additional borrowing capacity in support of the Company’s future growth objectives. These new senior secured credit facilities (the “Facili
Mon, 15 Jan 2024 18:29:40 +0000	Owning 49% shares,institutional owners seem interested in MiMedx Group, Inc. (NASDAQ:MDXG), Key Insights Given the large stake in the stock by institutions, MiMedx Group's stock price might be vulnerable to...
Wed, 03 Jan 2024 12:09:00 +0000	MDXG: Axiofill Update & Series B Conversion By John Vandermosten, CFA NASDAQ:MDXG READ THE FULL MDXG RESEARCH REPORT Corporate Updates MiMedx Group, Inc. (NASDAQ:MDXG) has updated investors on two important events over the last few weeks. Most recently, the company announced that the FDA issued a Warning Letter related to Axiofill’s classification as a Section 361 product. Recall that Axiofill was launched in Fall of 2022 as an acellular